International Circulation: International Circulation is honored to speak to Professor Suzanne Oparil on the occasion of WHC2009 in Beijing and this Chinese guidelines preparatory meeting.
We know the ESH/ESC and the Japanese JSH just updated their guidelines for hypertension management， and China and the United States are also in the process of updating their hypertension guidelines. From your perspective， why are organizations updating their hypertension guidelines now in the last couple of years?
《国际循环》：我们知道ESH/ESC和日本JSH刚刚更新了高血压治疗指南，现在，中国和美国也正在更新高血压指南。在您看来，为什么这些年来，这些组织都在不断地更新指南？

Prof Oparil: We are working very hard on this. The reason is that there is a lot of new evidence in the literature based on randomized controlled trials of antihypertensive treatment. We believe very strongly that every piece of guidance that is given to physicians should be based on evidence in the form of randomized controlled trials as randomization eliminates bias and eliminates expert opinion. Because there have been so many new trials， there are many new guidelines being constructed.
Prof Oparil：我们一直在致力于指南的修订是因为：这几年有很多新的抗高血压治疗方面的临床随机数据出台。对临床医生进行指导的指南中，任何一项决策都应以随机临床对照试验的证据为基础，去除其片面性和专家个人意见，这一点我们深信不移。因为已经有许多新的临床试验结果，所以相应的，指南也有许多方面需要更新修订。